Evidence map›Paper›PMID 37081574›Full record

ArticleTrials2023

Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study.

Sophia Lengsfeld, Thilo Burkard, Andrea Meienberg, Nica Jeanloz, David Coynel, Deborah R Vogt, Lars G Hemkens, Benjamin Speich, Davide Zanchi, Tobias E Erlanger and 2 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03204396 (Smoking Cessation Facilitated by Glucagon-like Peptide-1), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03204396 phase2completednot on this map

Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues - a Randomized, Double-blind, Placebo-controlled Trial

TypeinterventionalSponsorUniversity Hospital, Basel, SwitzerlandRan2017 to 2022Enrolled256ConditionsGlucagon-like Peptide-1, Smoking Cessation, Weight Change, Body, CravingArmsDulaglutide, 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 4 countries.

Sophia LengsfeldEndocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Thilo BurkardMedical Outpatient Department, University Hospital Basel, Petersgraben 4, Basel, 4031, Switzerland.
Andrea MeienbergMedical Outpatient Department, University Hospital Basel, Petersgraben 4, Basel, 4031, Switzerland.
Nica JeanlozEndocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
David CoynelDivision of Cognitive Neuroscience, Department of Psychology and Transfaculty Research Platform, University of Basel, Basel, Switzerland.
Deborah R VogtEndocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Lars G HemkensResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel and University Hospital of Basel, Basel, Switzerland.
Benjamin SpeichResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel and University Hospital of Basel, Basel, Switzerland.
Davide ZanchiRoche Innovation Centre Basel, F. Hoffmann- La Roche, Basel, Switzerland.
Tobias E ErlangerDepartment of Clinical Research, University of Basel and University Hospital of Basel, Basel, Switzerland.
Mirjam Christ-CrainEndocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Bettina WinzelerEndocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. bettina.winzeler@usb.ch.ORCID http://orcid.org/0000-0001-8305-2700
University of Basel · CHUniversity Hospital of Basel · CHRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCigarette smoking is the leading preventable cause of premature death. Despite dedicated programmes, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduce energy intake and body weight and seem to modulate addictive behaviour. These GLP-1 properties are of major interest in the context of smoking cessation. The aim of this study is to evaluate the GLP-1 analogue dulaglutide as a new therapy for smoking cessation.

methodsThis is a placebo-controlled, double-blind, parallel group, superiority, single-centre randomized study including 255 patients. The intervention consists of a 12-week dulaglutide treatment phase with 1.5 mg once weekly or placebo subcutaneously, in addition to standard of care (behavioural counselling and pharmacotherapy with varenicline). A 40-week non-treatment phase follows. The primary outcome is the point prevalence abstinence rate at week 12. Smoking status is self-reported and biochemically confirmed by end-expiratory exhaled carbon monoxide measurement. Further endpoints include post-cessational weight gain, nicotine craving analysis, glucose homeostasis and long-term nicotine abstinence. Two separate substudies assess behavioural, functional and structural changes by functional magnetic resonance imaging and measures of energy metabolism (i.e. resting energy expenditure, body composition). DISCUSSION: Combining behavioural counselling and medical therapy, e.g. with varenicline, improves abstinence rates and is considered the standard of care. We expect a further increase in quit rates by adding a second component of medical therapy and assume a dual effect of dulaglutide treatment (blunting nicotine withdrawal symptoms and reducing post-cessational weight gain). This project is of high relevance as it explores novel treatment options aimed at preventing the disastrous consequences of nicotine consumption and obesity.

trial registrationClinicalTrials.gov NCT03204396 . Registered on June 26, 2017.

Indexed as

Smoking CessationSubstance Withdrawal SyndromeDouble-Blind MethodEquivalence Trials as TopicGlucagon-Like Peptide 1HumansNicotineRandomized Controlled Trials as TopicVareniclineWeight GainGlucagon-Like Peptide 1NicotineVareniclineCigarette smokingDiabetesDulaglutideGLP-1 analoguesNicotine addictionNicotine cravingPrevalence abstinence rateVareniclineWeight gain

Identifiers

PMID37081574
PMCPMC10120253
OpenAlexW4366595992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.